BLEX 404 Oral Liquid

Phase 2Small molecule

BLEX 404 Oral Liquid is one of 82 small molecule programs targeting Chronic Myelomonocytic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myelomonocytic LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Chronic Myelomonocytic LeukemiaPhase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Prolia

Amgen

Preclinical

14 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 6

BLEX 404 Oral Liquid

BBioLite, Inc.

Phase 2

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Not yet recruiting

Breast Cancer

NCT02802423

Q2 2028

Phase 2Not yet recruiting

Chronic Myelomonocytic Leukemia

NCT02944955

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Not yet recruiting·BBioLite, Inc.·Phase 1/2·NCT02802423·44 enrolled

Chronic Myelomonocytic Leukemia1 trial

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Not yet recruiting·BBioLite, Inc.·Phase 2·NCT02944955·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BLEX 404 Oral Liquid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BLEX 404 Oral Liquid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BLEX 404 Oral Liquid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioLite, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioLite, Inc.

BLEX 404 Oral Liquid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Trials by Indication[1]

Breast Cancer1 trial

Chronic Myelomonocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News